ORNBV Orion Oyj Class B

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

ORION CORPORATION

PRESS RELEASE

29 January 2024 at 15.00 EET

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

Orion will publish Financial Statement Release for 2023 on Tuesday, 13 February 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at  after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media representatives will be held on Tuesday, 13 February 2024 at 13.30 EET.

A link to the live webcast is available on Orion's website at . A recording of the event will be available on the website later the same day.

Confenrence call can be joined by registering through the following link:

Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be presented in writing through the question form of the webcast.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

                                                

Contact person:

Tuukka Hirvonen, Investor Relations, Orion Corporation

tel. +358 10 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
29/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

337,000 Orion Corporation A shares converted into B shares

337,000 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 20 AUGUST 2025 at 9.00 EEST         337,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 337,000 A shares have been converted into 337,000 B shares. The conversion has been entered into the Trade Register on 20 August 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,971,...

 PRESS RELEASE

337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         20.8.2025 KLO 9.00          337 000 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 337 000 A-osaketta 337 000 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 20.8.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 31 971 783 kpl ja B-osakkeita 109 162 495 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä...

Orion Oyj: 1 director

A director at Orion Oyj sold 4,000 shares at 64.481EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

 PRESS RELEASE

Orion Corporation: Managers’ transactions – Juhani Kankaanpää

Orion Corporation: Managers’ transactions – Juhani Kankaanpää ORION CORPORATION MANAGERS’ TRANSACTIONS 8 AUGUST 2025 at 9.30 EEST         Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Juhani KankaanpääPosition...

 PRESS RELEASE

Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää

Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää ORION OYJ        JOHTOHENKILÖIDEN LIIKETOIMET         8.8.2025 KLO 9.30          Orion Oyj: Johtohenkilöiden liiketoimet – Juhani Kankaanpää Orion Oyj on saanut seuraavan Markkinoiden väärinkäyttöasetuksen (EU) N:o 596/2014 mukaisen ilmoituksen johtohenkilön tai johtohenkilön lähipiirin liiketoimista Orionin osakkeilla tai muilla Orioniin liittyvillä rahoitusvälineillä. Orion Oyj - Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Juhani KankaanpääAsema: Muu ylin johtoLiikkeeseenlaskija: Or...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch